Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2018-04-24 | Robert J. Hombach, 52, September 2017, Former Chief Financial Officer & Chief Operations Officer, Baxalta Inc.; Director, CarMax, Inc. |
| 2019-04-23 | Robert J. Hombach, 53, September 2017, Former Executive Vice President, Chief Financial Officer & Chief Operations Officer, Baxalta Inc.; Director, CarMax, Inc.; Director, Aptinyx Inc. |
| 2020-04-14 | Robert J. Hombach joined our Board in September 2017 and currently serves as the Chair of the Audit Committee. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc. |
| 2021-04-13 | Robert J. Hombach joined our Board in September 2017 and currently serves as the Chair of the Audit Committee. He served as Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc., a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. The Compensation Committee is currently composed of four directors: Mr. Grey (Chair), Ms. Anderson, Mr. Hombach and Dr. Pyott. 2020 INDEPENDENT DIRECTOR COMPENSATION: Robert J. Hombach Fees Earned ($) 101,500 Stock Awards ($) 458,810 Total ($) 560,310. |
| 2022-04-12 | Robert J. Hombach, 55, Director Since September 2017, Former Executive Vice President, CFO & Chief Operations Officer, Baxalta Inc.; Director, Aptinyx Inc; Director, CarMax, Inc. Chair of the Audit Committee. Compensation Committee Member. 2021 INDEPENDENT DIRECTOR COMPENSATION: Fees Earned or Paid in Cash $101,500, Stock Awards $397,312, Total $498,812. |
| 2023-04-11 | Robert J. Hombach joined our Board in September 2017 and currently serves as Chair of the Audit Committee. Mr. Hombach served as Executive Vice President, CFO, and Chief Operations Officer of Baxalta Inc., a public biopharmaceutical company spun out in June 2015 from Baxter International Inc., a public pharmaceutical company, until it was acquired by Shire PLC in June 2016. Mr. Hombach served as Corporate Vice President and CFO of Baxter from July 2010 until the spin-off in June 2015. Mr. Hombach also served as Treasurer of Baxter from 2007 to 2011 and was Vice President of Finance, Europe, Middle East and Africa from 2004 to 2007. Prior to that, Mr. Hombach served in a number of finance positions of increasing responsibility in the corporate planning, manufacturing, operations and treasury areas at Baxter. Mr. Hombach currently serves on the boards of Aptinyx Inc., a public biopharmaceutical company, and Embecta Corporation, a public diabetes company. Previously, Mr. Hombach served on the board of CarMax, Inc., a public company, from April 2018 to June 2022, and the board of Naurex, Inc., a private pharmaceutical company acquired by Allergan in 2015. Mr. Hombach earned an M.B.A. from Northwestern University’s J.L. Kellogg Graduate School of Management, and a B.S. in Finance cum laude from the University of Colorado. |
| 2024-04-09 | Robert J. Hombach joined our Board in September 2017 and currently serves as Chair of the Audit Committee. ... 2023 Independent Director Compensation ... Robert J. Hombach 101,500 Fees Earned or Paid in Cash, 385,438 Stock Awards, 486,938 Total. |
| 2025-04-08 | Robert J. Hombach joined our Board in September 2017 and currently serves as Chair of the Audit Committee. Mr. Hombach served as Executive Vice President, CFO and COO of Baxalta Inc. 2024 Non-Employee Director Compensation: Robert J. Hombach received total compensation of $467,045. |
| Filing Date | Source Excerpt |
|---|---|
| 2018-05-04 | Mr. Hombach is the retired Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta, a biopharmaceutical company. |
| 2019-05-06 | Mr. Hombach is the retired Executive Vice President, Chief Financial Officer and Chief Operations Officer of Baxalta, a biopharmaceutical company, a position he held from 2015 until the acquisition of Baxalta by Shire PLC in 2016. |
| 2020-05-08 | Mr. Hombach’s considerable executive and financial experience qualify him to serve on our Board. |
| 2021-05-11 | Mr. Hombach’s considerable executive and financial experience qualify him to serve on our Board. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22